Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours

drug protocol number
1403-0011
drug sponsor
Boehringer Ingelheim Middle East & North Africa (Scientific Office) FZ Limited
drug study
BI 907828/ brigimadlin
drug trial site
King Abdulaziz Medical City NG (Riyadh)
drug status
Ongoing
drug phase